Spansa Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 21-12-2024
- Paid Up Capital ₹ 0.10 M
as on 21-12-2024
- Company Age 12 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.97 Cr
as on 21-12-2024
- Revenue 25.47%
(FY 2021)
- Profit 23.50%
(FY 2021)
- Ebitda 30.27%
(FY 2021)
- Net Worth 34.97%
(FY 2021)
- Total Assets 42.05%
(FY 2021)
About Spansa Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.97 Cr.
Ayush Kediya, Anuj Kedia, and Ram Jayaswal serve as directors at the Company.
- CIN/LLPIN
U24232BR2012PTC019175
- Company No.
019175
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Sep 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Company Details
- Location
Patna, Bihar, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Spansa Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ayush Kediya  | Director | 03-Sep-2012 | Current |
| Anuj Kedia | Director | 29-Oct-2018 | Current |
| Ram Jayaswal | Director | 27-Jul-2021 | Current |
Financial Performance of Spansa Pharmaceuticals.
Spansa Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 25.47% increase. The company also saw a substantial improvement in profitability, with a 23.5% increase in profit. The company's net worth Soared by an impressive increase of 34.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Spansa Pharmaceuticals?
In 2021, Spansa Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 21 Aug 2023 | ₹1.70 M | Open |
Hdfc Bank Limited Creation Date: 23 Jul 2021 | ₹3.04 M | Open |
Hdfc Bank Limited Creation Date: 31 Jan 2019 | ₹1.50 Cr | Open |
How Many Employees Work at Spansa Pharmaceuticals?
Spansa Pharmaceuticals has a workforce of 0 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Spansa Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Spansa Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
